[go: up one dir, main page]

BR9811994A - Suspensão farmacêutica compreendendo hemi-hidrato de nevirapina - Google Patents

Suspensão farmacêutica compreendendo hemi-hidrato de nevirapina

Info

Publication number
BR9811994A
BR9811994A BR9811994-0A BR9811994A BR9811994A BR 9811994 A BR9811994 A BR 9811994A BR 9811994 A BR9811994 A BR 9811994A BR 9811994 A BR9811994 A BR 9811994A
Authority
BR
Brazil
Prior art keywords
pharmaceutical suspension
nevirapine hemihydrate
nevirapine
hemihydrate
pharmaceutical
Prior art date
Application number
BR9811994-0A
Other languages
English (en)
Other versions
BR9811994B1 (pt
Inventor
Karl Georg Grozinger
Amale A Hawi
Original Assignee
Boehringer Ingelheim Pharmacel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22006658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9811994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharmacel filed Critical Boehringer Ingelheim Pharmacel
Publication of BR9811994A publication Critical patent/BR9811994A/pt
Publication of BR9811994B1 publication Critical patent/BR9811994B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"SUSPENSãO FARMACêUTICA COMPREENDENDO HEMI-HIDRATO DE NEVIRAPINA"<D>. Uma suspensão farmacêutica aquosa consistindo essencialmente em hemi-hidrato de nevirapina tendo um tamanho de partícula entre cerca de 1 e 150 mícrons de diâmetro.
BRPI9811994-0B1A 1997-08-25 1998-08-11 Composição farmacêutica compreendendo hemi-hidrato de nevirapina BR9811994B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5680397P 1997-08-25 1997-08-25
PCT/US1998/016581 WO1999009990A1 (en) 1997-08-25 1998-08-11 Pharmaceutical suspension comprising nevirapine hemihydrate

Publications (2)

Publication Number Publication Date
BR9811994A true BR9811994A (pt) 2000-09-05
BR9811994B1 BR9811994B1 (pt) 2013-11-19

Family

ID=22006658

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9811994-0B1A BR9811994B1 (pt) 1997-08-25 1998-08-11 Composição farmacêutica compreendendo hemi-hidrato de nevirapina

Country Status (37)

Country Link
US (2) US6172059B1 (pt)
EP (1) EP1019058B1 (pt)
JP (1) JP3472261B2 (pt)
KR (1) KR100426516B1 (pt)
CN (1) CN1197578C (pt)
AR (2) AR016869A1 (pt)
AT (1) ATE326971T1 (pt)
AU (1) AU742761B2 (pt)
BG (1) BG64337B1 (pt)
BR (1) BR9811994B1 (pt)
CA (1) CA2301646C (pt)
CL (1) CL2008003111A1 (pt)
CO (1) CO4970742A1 (pt)
CY (1) CY1105228T1 (pt)
CZ (1) CZ290667B6 (pt)
DE (1) DE69834655T2 (pt)
DK (1) DK1019058T3 (pt)
EG (1) EG24075A (pt)
ES (1) ES2265666T3 (pt)
HR (1) HRP980461B1 (pt)
HU (1) HU226063B1 (pt)
ID (1) ID21650A (pt)
IL (1) IL134185A (pt)
MY (1) MY122272A (pt)
NO (1) NO326226B1 (pt)
NZ (1) NZ503414A (pt)
PE (1) PE105799A1 (pt)
PL (1) PL192361B1 (pt)
PT (1) PT1019058E (pt)
RS (1) RS49808B (pt)
RU (1) RU2196584C2 (pt)
SA (1) SA98190680B1 (pt)
TR (1) TR200000490T2 (pt)
TW (1) TW450812B (pt)
UA (1) UA44370C2 (pt)
WO (1) WO1999009990A1 (pt)
ZA (1) ZA987623B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092095A1 (en) * 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
CA2479943A1 (en) * 2002-04-23 2003-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Method for reduction of residual organic solvent in carbomer
NZ566796A (en) * 2005-08-31 2011-04-29 Cipla Ltd Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
US20110082161A1 (en) * 2008-06-30 2011-04-07 Lieven Elvire Colette Baert Powders for reconstitution
EP2499141B1 (en) * 2009-11-10 2013-07-24 The North West University Nevirapine polymorph
BR112012014762A2 (pt) * 2009-12-17 2016-03-29 Univ Northwest forma polimorfa de nevirapina e sua preparação

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
DE69007891T2 (de) * 1989-06-28 1994-08-25 Boehringer Ingelheim Pharma 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one und -thione und ihre Verwendung bei der AIDS-Vorbeugung oder -Behandlung.
CA2030056C (en) * 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5571912A (en) * 1990-10-19 1996-11-05 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines
GB9215178D0 (en) * 1992-07-16 1992-08-26 Glaxo Group Ltd Antiviral combinations
CA2178760C (en) * 1993-12-15 2000-08-01 Joel R. Huff Hiv protease inhibitors
DE4403311C1 (de) * 1994-02-03 1995-04-20 Boehringer Ingelheim Kg Verfahren zur Herstellung von Nevirapine (11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4-diazepin]-6-on)

Also Published As

Publication number Publication date
UA44370C2 (uk) 2002-02-15
AR016869A1 (es) 2001-08-01
CY1105228T1 (el) 2010-03-03
CN1197578C (zh) 2005-04-20
PE105799A1 (es) 1999-11-16
DE69834655D1 (de) 2006-06-29
IL134185A0 (en) 2001-04-30
WO1999009990A1 (en) 1999-03-04
AU8777198A (en) 1999-03-16
AU742761B2 (en) 2002-01-10
EP1019058B1 (en) 2006-05-24
HK1027975A1 (en) 2001-02-02
JP2001513564A (ja) 2001-09-04
IL134185A (en) 2005-11-20
EP1019058A1 (en) 2000-07-19
US6255481B1 (en) 2001-07-03
CA2301646A1 (en) 1999-03-04
NZ503414A (en) 2002-11-26
YU9800A (sh) 2001-12-26
HU226063B1 (hu) 2008-04-28
CZ290667B6 (cs) 2002-09-11
CL2008003111A1 (es) 2009-09-11
KR20010023257A (ko) 2001-03-26
NO20000906L (no) 2000-02-24
DK1019058T3 (da) 2006-06-12
RU2196584C2 (ru) 2003-01-20
DE69834655T2 (de) 2006-12-14
ZA987623B (en) 2000-03-22
TW450812B (en) 2001-08-21
ES2265666T3 (es) 2007-02-16
PT1019058E (pt) 2006-08-31
TR200000490T2 (tr) 2000-08-21
BG104133A (bg) 2000-08-31
BR9811994B1 (pt) 2013-11-19
MY122272A (en) 2006-04-29
HUP0003093A2 (hu) 2001-08-28
ATE326971T1 (de) 2006-06-15
PL192361B1 (pl) 2006-10-31
CA2301646C (en) 2008-11-18
HRP980461A2 (en) 1999-06-30
PL338828A1 (en) 2000-11-20
RS49808B (sr) 2008-08-07
NO326226B1 (no) 2008-10-20
BG64337B1 (bg) 2004-10-29
NO20000906D0 (no) 2000-02-24
AR083451A2 (es) 2013-02-27
ID21650A (id) 1999-07-08
SA98190680B1 (ar) 2006-04-04
CZ2000694A3 (cs) 2000-09-13
HRP980461B1 (en) 2002-08-31
JP3472261B2 (ja) 2003-12-02
US6172059B1 (en) 2001-01-09
KR100426516B1 (ko) 2004-04-13
EP1019058A4 (en) 2004-11-10
EG24075A (en) 2008-05-11
CO4970742A1 (es) 2000-11-07
CN1268055A (zh) 2000-09-27

Similar Documents

Publication Publication Date Title
IS5409A (is) Útskipt karboxamídóþíasól, framleiðsla þeirra og lyfjablöndur sem innihalda þau
BR9915548A (pt) Proteìnas de fusão de interferon-beta e usos
MY102037A (en) Hydrosols of pharmacologically active agents and their pharmaceutical compositions
PL324660A1 (en) Derivatives of n-heteroarylpyridin sulphonamide and their application as endotheline antagonists
AU5241199A (en) Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
EP0811013A4 (en) ISOLATED NONAPEPTIDES PRESENTED BY HLA MOLECULES, AND USE THEREOF
PT1041972E (pt) Comprimido para a libertacao instantanea e prolongada de uma ou mais substancias activas
BR9916857A (pt) 4 heteroaril diarilaminas
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
DE69836424D1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
BR9808895A (pt) Partìcula de detergente
BR9913737A (pt) Preparação farmacêutica
DE69818026D1 (de) Wässrige suspension zur nasalen verabreichung von loteprednol
BR9811994A (pt) Suspensão farmacêutica compreendendo hemi-hidrato de nevirapina
AU2001259676A1 (en) Nanosized particles of molybdenum sulfide and derivatives and uses thereof
AU2456701A (en) Pharmaceutical and veterinary uses of endothelin antagonists
HUP0102007A3 (en) Semi-solid aqueous pharmaceutical preparations for oral applications of toltrazuril sulphone
AU3681795A (en) Polypeptide agonists and antagonists of human interleukin-8
BR9713514A (pt) Novo uso de creatina
AU2712197A (en) Micellar aqueous composition and method for solubilizing hydrophobic drug
MX9702506A (es) Suspensiones orales de sabeluzol.
ECSP982627A (es) Suspension farmaceutica que comprende hemihidrato de nevirapina
BR9909529A (pt) Maleato de paroxetina
AU580890B2 (en) P-acylaminobenzamides
AU2001297556A1 (en) 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: APRESENTAR A TRADUCAO SIMPLES DO DOCUMENTO HABIL DA ORIGEM

B06J Correction of requirement [chapter 6.10 patent gazette]

Free format text: APRESENTAR COPIA DE DOCUMENTO, CONFORME ART. 34 DA LPI 9279/96.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O, 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/11/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2318 DE 09-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.